ArticleAmerican journal of translational research2026
Prognostic factors and treatment outcomes in nasopharyngeal carcinoma patients with liver metastasis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Clinical-Radiomics Nomogram Based on Pretreatment Magnetic Resonance Imaging Predicting Tumor Residual at the End of Radiotherapy in Patients With Nasopharyngeal Carcinoma.International journal of biomedical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the risk factors for liver metastasis (LM) in patients with nasopharyngeal carcinoma (NPC) and to compare the long-term survival outcomes between surgical resection and transcatheter arterial chemoembolization (TACE) in patients who developed LM.
methodsA retrospective analysis was conducted on 98 patients with NPC treated at our hospital between January 2021 and March 2025. Patients were stratified into an LM group (n = 38) and a non-LM group (n = 60). Univariate and multivariate logistic regression analyses were performed to identify factors associated with LM. Among LM patients, long-term survival was compared between those undergoing partial hepatectomy (n = 20) and those treated with TACE (n = 18).
resultsNo significant differences were observed between the LM and non-LM groups in terms of age, BMI, tumor size, GPS score, KPS score, ALT level, or comorbidities (all P > 0.05). However, significant differences were found in gender (male: 73.7% vs. 50.0%, P = 0.026), TNM stage (stage III: 65.8% vs. 31.7%, P < 0.01), AST level (42.6 ± 18.3 U/L vs. 28.4 ± 12.1 U/L, P = 0.003), chemotherapy usage (57.9% vs. 85.0%, P = 0.004), and HBsAg positivity (34.2% vs. 11.7%, P = 0.008). Multivariate analysis identified male gender (OR = 2.45, 95% CI: 1.12-5.36), TNM stage III (OR = 3.82, 95% CI: 1.75-8.35), elevated AST (OR = 1.04 per U/L, 95% CI: 1.01-1.07), absence of chemotherapy (OR = 3.12, 95% CI: 1.42-6.85), and HBsAg positivity (OR = 3.58, 95% CI: 1.52-8.41) as independent risk factors for LM. Among LM patients, the 3-year overall survival rate was significantly higher in the hepatectomy group compared to the TACE group (65.0% vs. 33.3%, log-rank P = 0.021).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.